Physician profile
Sherry Maragh
NPI 1366407157
$11,867.89
in general payments reported to CMS, 2019-2025
43 companies · $2,577 in 2025
The $2,577 reported for 2025 was more than what 92% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $1,128 · 2021: $930 · 2022: $1,316 · 2023: $2,252 · 2024: $2,112 · 2025: $2,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,856 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,855.99 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,226.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $998.94 | 2019-2025 | |
| Galderma Laboratories, L.P. | $962.64 | 2019-2025 | Aklief, Oracea, Nemluvio |
| Abbvie INC. | $830.34 | 2019-2025 | |
| Incyte Corporation | $796.88 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $792.74 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Janssen Biotech, INC. | $605.65 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $590.73 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $569.56 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $553.88 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $435.75 | 2021-2025 | |
| Ucb, INC. | $423.45 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $380.08 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $309.80 | 2020-2025 | Dupixent, Libtayo |
| Encore Dermatology INC. | $236.10 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $214.69 | 2019-2025 | Clindacin Etz, Neo-Synalar |
| Amgen INC. | $193.53 | 2020-2024 | Otezla, Enbrel |
| Leo Pharma INC. | $143.13 | 2019-2023 | Adbry |
| Celgene Corporation | $126.01 | 2019 | |
| Organon LLC | $119.07 | 2025 | Vtama |
| Revance Therapeutics, INC. | $115.18 | 2024 | Daxxify |
| Kerecis Limited | $113.53 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $105.25 | 2023-2024 | Puraply |
| Mayne Pharma Commercial LLC | $102.71 | 2019-2020 | |
| Journey Medical Corporation | $96.17 | 2019-2022 | |
| Strata Skin Sciences, INC. | $95.85 | 2023 | Xtrac |
| Allergan, INC. | $92.89 | 2019-2022 | |
| Almirall LLC | $92.34 | 2019-2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $78.36 | 2020-2021 | |
| Dermira, INC. | $63.19 | 2020-2021 | |
| Epi Health, LLC | $52.04 | 2021-2022 | |
| Merz North America, INC. | $44.83 | 2019-2024 | |
| Glenmark Therapeutics INC. | $43.00 | 2019 | |
| Lumenis, INC | $41.35 | 2021 | |
| Verrica Pharmaceuticals INC. | $39.11 | 2023 | Ycanth |
| Dermavant Sciences, INC. | $34.86 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.54 | 2025 | Spevigo |
| Botanix Sb INC | $26.53 | 2025 | Sofdra |
| Convatec INC. | $24.09 | 2024 | |
| Biofrontera INC. | $20.07 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.82 | 2024 | Acthar |
| Taro Pharmaceuticals USA, INC. | $15.41 | 2019 | |
| Tactile Systems Technology INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Maragh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.